Loading...
Docoh

Sensei Biotherapeutics (SNSE)

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company has developed a proprietary bacteriophage-based platform, ImmunoPhage™, that enables the rapid generation of immune activating therapeutic agents that fully engage the immune system. Using the ImmunoPhage™ platform, Sensei is developing a library of ImmunoPhage, called Phortress™, to target multiple tumor-associated antigens to create a personalized yet off-the-shelf cocktail approach for treating cancer patients. The platform enables efficient, scalable and cost-effective manufacturing to support all of Sensei’s clinical programs. The company’s most advanced immunotherapy, SNS-301, a first-in-class ImmunoPhage™ targeting the tumor antigen Aspartyl beta Hydroxylase (ASPH), is currently in a Phase 1/2 clinical trial in patients with advanced Squamous Cell Carcinoma of the Head and Neck. Earlier stage programs include SNS-401, a ImmunoPhage™ cocktail for the treatment of Merkel Cell Carcinoma, and SNS-VISTA, an antibody-based therapeutic targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA).

SNSE stock data

Press releases

From Benzinga Pro

Calendar

9 Aug 22
30 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 9.9M 9.9M 9.9M 9.9M 9.9M 9.9M
Cash burn (monthly) (no burn) 475K 3.57M 3.58M 3.97M 3.01M
Cash used (since last report) n/a 1.44M 10.83M 10.85M 12.03M 9.13M
Cash remaining n/a 8.46M -935K -955.23K -2.14M 772.73K
Runway (months of cash) n/a 17.8 -0.3 -0.3 -0.5 0.3

Beta Read what these cash burn values mean

My notes
No notes yet
My annotations
No annotations yet

Community content

Community notes
No notes yet
Community annotations
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 Jun 22 Bob Holmen Common Stock Grant Acquire A No No 0 4,466 0 21,132
10 Jun 22 Bob Holmen Stock Option Common Stock Grant Acquire A No No 2.05 14,550 29.83K 14,550
10 Jun 22 Deneen Vojta Common Stock Grant Acquire A No No 0 4,466 0 4,466
10 Jun 22 Deneen Vojta Stock Option Common Stock Grant Acquire A No No 2.05 14,550 29.83K 14,550
10 Jun 22 Jessie English Common Stock Grant Acquire A No No 0 4,466 0 4,466
10 Jun 22 Jessie English Stock Option Common Stock Grant Acquire A No No 2.05 14,550 29.83K 14,550
10 Jun 22 Thomas G Ricks Common Stock Grant Acquire A No No 0 4,466 0 4,466
10 Jun 22 Thomas G Ricks Stock Option Common Stock Grant Acquire A No No 2.05 14,550 29.83K 14,550
34.2% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 44 47 -6.4%
Opened positions 11 43 -74.4%
Closed positions 14 0 NEW
Increased positions 7 0 NEW
Reduced positions 16 0 NEW
13F shares Current Prev Q Change
Total value 56.14M 57.29M -2.0%
Total shares 20.71M 21.14M -2.1%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Cambrian BioPharma 5.23M $30.34M 0.0%
James Peyer 4.69M $0 0.0%
H&S Investments I 4.44M $0 0.0%
Apeiron Investment 3.23M $18.73M 0.0%
Ra Capital Management 723.55K $1.64M NEW
Vanguard 669.57K $1.52M -11.4%
Newtyn Management 415K $942K NEW
Renaissance Technologies 247K $561K +196.9%
BLK Blackrock 178.89K $406K -84.7%
Millennium Management 133.71K $304K +168.8%
Largest transactions Shares Bought/sold Change
BLK Blackrock 178.89K -989.12K -84.7%
Ra Capital Management 723.55K +723.55K NEW
Newtyn Management 415K +415K NEW
STT State Street 25.77K -199.8K -88.6%
Geode Capital Management 91.9K -163.93K -64.1%
Renaissance Technologies 247K +163.81K +196.9%
JPM JPMorgan Chase & Co. 1.3K -155.06K -99.2%
NTRS Northern Trust 15.54K -138.62K -89.9%
Ergoteles 93.6K +93.6K NEW
Vanguard 669.57K -86.38K -11.4%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: DC, disposition, entertainment, feedback, found, glycoprotein, hybrid, July, people
Removed: announced, China, community, delivery, distancing, emergency, exposure, globally, implemented, international, organization, origin, originating, outbreak, point, rapid, remotely, replacing, social, strain, virtual, working, Wuhan